Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?
Semin Liver Dis DOI: 10.1055/s-0040-1722646The past decade has seen a rise in the availability of breakthrough therapeutic strategies for treatment of hepatocellular carcinoma (HCC). A tumor microenvironment in HCC is regulated by various immunotolerance mechanisms; therefore, therapeutic strategies aiming at disrupting tumor immune tolerance are becoming attractive curative options in HCC. Immune checkpoint inhibitors have demonstrated impressive effectiveness in HCC, including in sorafenib-unresponsive patients. Synergistic approaches with checkpoint inhibitors (anti-PD-1/PD-L1 and CTLA-4) and antiangiogenic drugs are burgeoning as first-line treatment therapeutic modalities in HCC. [...] Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USAArticle in Thieme eJournals: Table of contents | Abstract | Full text
Source: Seminars in Liver Disease - Category: Gastroenterology Authors: Uson Junior, Pedro Luiz Serrano Nagalo, Bolni Marius Ahn, Daniel H. Bekaii-Saab, Tanios Borad, Mitesh J. Tags: Review Article Source Type: research
More News: Cancer & Oncology | Carcinoma | Gastroenterology | Hepatocellular Carcinoma | Immunotherapy | Liver | Liver Cancer | Liver Disease | Urology & Nephrology